COPD drug fails in phase 3 trial
CNBC's Angelica Peebles joins 'Squawk Box' to discuss the latest details on a COPD drug failure.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Sanofi (ENXTPA:SAN) Reports Positive Phase 3 Results for Itepekimab in COPD Trial
Sanofi announced that its AERIFY-1 trial with Regeneron Pharmaceuticals successfully met its primary endpoint, indicating progress in COPD treatment. Despite this positive news, the company's share price fell 5% over the last week, contrasting with a 2% rise in the broader market. This decline may reflect investors' reactions to other company initiatives, such as its partnership with Stagecoach Performing Arts to raise awareness of autoimmune Type 1 diabetes. These positive developments, although promising, were not enough to counterbalance the broader market's upward trend, contributing weight against Sanofi's price movement. Buy, Hold or Sell Sanofi? View our complete analysis and fair value estimate and you decide. Uncover the next big thing with financially sound penny stocks that balance risk and reward. The recent successful completion of Sanofi's AERIFY-1 trial could have a positive impact on its revenue and earnings forecasts by strengthening its position in the COPD treatment market. However, despite these promising developments, the company's share price experienced a 5% decline in the past week, contrasting with the broader market's 2% rise. This movement might reflect investor reactions to other company initiatives, such as the partnership with Stagecoach Performing Arts, and broader market trends. Looking at a longer-term context, Sanofi's shares have delivered a total return of 19.59% over the past five years. Recent performance has exceeded the French Pharmaceuticals industry and market, which returned 4% and 4.5% declines respectively over the last year. Such outperformance indicates resilience amidst industry challenges and market volatility. Please consider the current share price of €95.9 against the consensus price target of €117.17, indicating a potential upside potential of approximately 18.5%. This price target is based on expectations of revenue reaching €51.2 billion and earnings of €10.2 billion by 2028, trading on a PE ratio of 16.1x. Analysts are assuming that Sanofi will enhance its growth trajectory driven by its innovative treatments and efficient operational strategies. Assess Sanofi's previous results with our detailed historical performance reports. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTPA:SAN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
2 days ago
- Yahoo
Doctors warn at-risk groups as Canadian wildfires bring haze to Chicago
The Brief Smoke from ongoing wildfires in Canada is drifting south, bringing hazy skies and worsening air quality to the Chicago area. Healthy individuals without pre-existing conditions may not notice any breathing issues, but the elderly, babies, and those with lung and heart conditions should take extra steps to prepare. Doctors recommend sensitive groups, such as those with asthma or COPD, should stay indoors, in a room with clean, filtered air. CHICAGO - Smoke from raging wildfires in Canada is drifting south, bringing hazy skies and worsening air quality to Chicagoland — a concern for sensitive groups and those preparing for outdoor events this weekend. What we know As thick haze from the north drifts into our region and air quality continues to decline, health experts are urging caution, particularly for individuals with certain pre-existing conditions. "The best way to handle the heavy or smoky condition is to avoid it if you can and stay inside," said Steve Mosakowski, director, Respiratory Care Services, Rush University Medical Center. Levels of fine particle pollution (PM2.5) were on the rise Friday and are expected to continue climbing throughout the weekend. That means sensitive groups will have a harder time breathing. "If you're inside, go to your clean room that you have set up in your house, run your air conditioner, keep your windows closed, your door closed, let that air conditioner run and cool things off and also filter some of that air. If you have an air filter, run that in that room so it keeps that room nice and clean," Mosakowski explained. Medical officials say it's important to understand the risks before lacing up and heading outdoors. Between Friday afternoon and evening, the air quality, according to shifted from 'good' to 'moderate'—and is expected to get worse. Most at risk of breathing difficulties are those with lung conditions like asthma and COPD, heart disease, the elderly, and babies. "If people are going to go outside and they have asthma or COPD, bring that inhaler with you and your spacer so that you can treat yourself should you need to," said Mosakowski. "But anybody who feels like they are struggling to breathe should seek immediate emergency help so that they can get the help they need." Mosakowski, who is also an assistant professor at Rush University's Department of Cardiopulmonary Sciences shares that you'll start to notice worsening air quality simply by looking outside. "It can give it that brown-ish or orange-ish reflection that we're going to see there. And that means that there's a lot more particles that are in the air that are reflecting that light," Mosakowski said. Healthy individuals without pre-existing conditions may not notice any breathing susceptible to breathing difficulties should also not burn candles or incense, which will further aggravate symptoms. What they're saying As the wind changed on Friday evening, haze hung over the Garfield Park Conservatory, where runners will take off for the Bank of America Chicago 13.1 (Half-Marathon) on Sunday."I've always been into humidity and even air quality and learning how it affects my running," said Jasmine Redmond-Winston, who is running in the race. "I am a little concerned but if it does clear up, that would be great." On Friday, race crews were hard at work preparing the course, which starts and ends in Garfield Park, while also extending into Douglass Park and Humboldt Park. "It's really cool to be on another side of the city that we don't really get a lot of exposure to, so that's really nice," Redmond-Winston said. Many runners and event organizers are keeping an eye on the sky—hopeful the haze won't cast a shadow on race day. "I'm excited to get back into it, you know the mix of emotions, the nerves and everything, the excitement, it's all kicking in," said Julian Rincon, who is running the Bank of America Chicago 13.1. What's next As the haze grows, local health officials and race organizers urge runners and residents to monitor air quality and adjust their activities as needed. The Bank of America Chicago Half Marathon kicks off at 6:50 a.m. Sunday with the Wheelchair Division, followed by the Open Division at 7 a.m. Packet pick-up will resume from 9 a.m. to 4 p.m. at the Roosevelt Collection on Saturday.
Yahoo
2 days ago
- Yahoo
Jim Cramer Notes Verona Pharma plc (VRNA) 'Loses a Lot of Money'
We recently published a list of . In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against other stocks that Jim Cramer discusses. Answering a caller's query about Verona Pharma plc (NASDAQ:VRNA), Cramer stated: 'That stock is a rocket ship. Again, very very speculative, because it loses a lot of money. Does have a couple things in the pipe that people like, but also has a huge amount of insider selling, frankly.' A patient in a clinic, taking a medication dose from a nebulizer to treat a respiratory disease. Verona Pharma (NASDAQ:VRNA) is a biopharmaceutical company developing treatments for respiratory diseases with limited treatment options. The company's lead therapy, Ohtuvayre, is designed to provide bronchodilation and anti-inflammatory benefits for conditions like COPD, cystic fibrosis, and asthma. Buckley Capital Advisors stated the following regarding Verona Pharma plc (NASDAQ:VRNA) in its Q1 2025 investor letter: 'Verona Pharma plc (NASDAQ:VRNA) has developed a product called ensifentrine (Ohtuvayre), a bronchodilator and anti-inflammatory agent for maintenance treatment of COPD. COPD, more commonly known as smoker's lung, is caused by pollution or smoking. Diagnosis of COPD lowers life expectancy by approximately 6 years. Symptoms of COPD are shortness of breath, cough, wheezing, and sputum. COPD affects approximately 400 million people worldwide, with 8.6m people treated in the United States. Overall, VRNA ranks 7th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of VRNA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VRNA and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
